Abstract
East Asian patients have reduced anti-ischemic benefits and increased bleeding risk during antithrombotic therapies compared with Caucasian patients. As potent P2Y 12 receptor inhibitors (e.g., ticagrelor and prasugrel) and direct oral anticoagulants are commonly used in current daily practice, the unique risk-benefit trade-off in East Asians has been a topic of emerging interest. In this article, we propose updated evidence and future directions of antithrombotic treatment in East Asian patients.
Original language | English |
---|---|
Pages (from-to) | 422-432 |
Number of pages | 11 |
Journal | Thrombosis and Haemostasis |
Volume | 121 |
Issue number | 4 |
DOIs | |
Publication status | Published - 2021 Apr 1 |
Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2020. Thieme. All rights reserved.
Keywords
- antiplatelet therapy
- bleeding risk
- direct oral anticoagulants
- ischemic risk
- race
ASJC Scopus subject areas
- Hematology